United Therapeutics UTHR Adcirca — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by United Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about United Therapeutics's adcirca — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is United Therapeutics's adcirca — total revenues?
- United Therapeutics (UTHR) reported adcirca — total revenues of $2.9M in Q1 2026.
- How has United Therapeutics's adcirca — total revenues changed year-over-year?
- United Therapeutics's adcirca — total revenues decreased by 51.7% year-over-year, from $6M to $2.9M.
- What is the long-term trend for United Therapeutics's adcirca — total revenues?
- Over 4 years (2021 to 2025), United Therapeutics's adcirca — total revenues has grown at a -14.4% compound annual growth rate (CAGR), from $55.9M to $30M.
- What does adcirca — total revenues mean?
- Represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeutic line. This metric tracks the top-line performance of the product before accounting for any cost of goods sold or operating expenses.